Comparison of glucose‐lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta‐analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: To assess the evidence supporting the choice of third‐line agents in adults with inadequately controlled type 2 diabetes. Materials and methods: We searched randomized controlled trials (RCTs) published between January 2000 and July 2017 that reported data on cardiometabolic outcomes and hypoglycaemia for glucose‐lowering agents added to metformin‐based dual treatments. Data were stratified by background therapy and RCT duration, and synthesized, when possible, with network meta‐analyses. Results: A total of 43 RCTs (16 590 participants) were included, with metformin combined with: sulphonylureas (SUs) in 20 RCTs; thiazolidinediones (TZDs) in 10; basal or rapid‐acting insulin in 6; dipeptidyl peptidase‐4 (DPP‐4) inhibitors in 3; glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in 2; and sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors in 2. When added to metformin and SUs, after 24 to 36 weeks, rapid‐acting insulin resulted in the largest reduction in glycated haemoglobin (HbA1c; 1.6% vs placebo), followed by GLP‐1RAs (1.0%), basal insulin (0.8%) and SGLT‐2 inhibitors (0.7%), with no difference between GLP‐1RAs and SGLT‐2 inhibitors; body weight increased with insulin treatment (~3 kg vs placebo), while the greatest reduction was observed for SGLT‐2 inhibitors compared with all other therapies. Limited data for hypoglycaemia indicated a similar risk for SGLT‐2 inhibitors and GLP‐1RAs. Results for third‐line agents added to metformin and TZDs were comparable, showing similar HbA1c reduction and risk of hypoglycaemia between SGLT‐2 inhibitors and GLP‐1RAs, and a slightly greater reduction in body weight with SGLT‐2 inhibitors vs GLP‐1RAs. Data for 52 to 54 weeks were more limited: added to metformin and a SU, TZDs, GLP‐1RAs or SGLT‐2 inhibitors reduced HbA1c to a similar extent but had different effects on body weight (7 kg and 5 kg more with TZDs vs SGLT‐2 inhibitors and GLP‐1RAs, respectively; 2 kg less when comparing SGLT‐2 inhibitors with GLP‐1RAs). Formal analyses could not be performed for any other dual therapy failure combinations because of the small number of available RCTs. Conclusions: Moderate‐quality evidence supports the choice of a third‐line agent only in patients on metformin combined with a SU or a TZD, with SGLT‐2 inhibitors performing generally better than other drugs. In suggesting third‐line agents, future guidelines should recognize the widely differing evidence on the various dual therapy failures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766 · cited 1×
“For each background dual therapy failure and duration of follow-up, we summarized the available evidence using network diagrams; we reported number of participants and events, pairwise and network metaanalyses results and ranking probabilities in tables; we displayed network meta-analysis results against a common comp…”
MethodGraphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473 · cited 1×
“For each background dual therapy failure and duration of follow-up, we summarized the available evidence using network diagrams; we reported number of participants and events, pairwise and network metaanalyses results and ranking probabilities in tables; we displayed network meta-analysis results against a common comp…”
MethodWhat to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734 · cited 1×
“5 if studies reported no participants with hypoglycaemia.(18) For each background dual therapy failure and duration of follow-up, we summarized the available evidence using network diagrams; we reported number of participants and events, pairwise and network metaanalyses results and ranking probabilities in tables; we…”
MethodEvaluating the quality of evidence from a network meta-analysis
Salanti, G., Del Giovane, C., Chaimani, A., Caldwell, D. M., & Higgins, J. P. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099682 · Cited by 1,402 · cited 6×
“SUs were the most common second agent combined with metformin (20 RCTs; 46.5%), followed by TZDs (10; 23.2%), basal or rapid-acting insulin (6; 13.9%), DPP-4 inhibitors (3; 7.0%), GLP-1RAs (2; 4.6%), or SGLT-2 inhibitors (2; 4.6%); references of included studies are reported in Appendix S1.”
MethodInfluentialWhite, I. R., Barrett, J. K., Jackson, D., & Higgins, J. P. T. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1045 · Cited by 1,114
Conceptual and technical challenges in network meta-analysis
Cipriani, A., Higgins, J. P. T., Geddes, J. R., & Salanti, G. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00008 · Cited by 1,072 · cited 1×
“Lastly, the present meta-analysis shares the drawbacks common to other network meta-analyses.(35) It is not possible to deliver individualized care to patients with type 2 diabetes without a coherent understanding of the relative efficacy and safety of available therapeutic options.”
Vaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A. P., Rivellese, A. A., Squatrito, S., Giorda, C. B., Sesti, G., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30317-0 · Cited by 292
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Self-citation
Metadata
- Authors
- Zaccardi, F., Dhalwani, N. N., Dales, J., Mani, H., Khunti, K., Davies, M. J., & Webb, D. R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-01-08
- Volume
- 20
- Issue
- 4
- Pages
- 985-997
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2774592377
- Cited by
- 30
- References
- 11
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.